Suppr超能文献

含维生素 C 和锌的多种草药配方(Immumax)治疗普通感冒的疗效和安全性。

Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management of the common cold.

机构信息

Green Clinic, Alexandria, Egypt.

出版信息

Int J Gen Med. 2011 Jan 12;4:45-51. doi: 10.2147/IJGM.S16266.

Abstract

OBJECTIVE

To study the potential efficacy and tolerability of a natural multiherbal formula (Immumax) containing Echinacea extract 120 mg, garlic powder 100 mg, Nigella sativa oil 200 mg, and Panax ginseng extract 50 mg plus vitamin C 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the common cold.

DESIGN AND SETTING

The study was conducted in a prospective, double-blind, randomized, controlled study design in an outpatient setting.

PATIENTS AND METHODS

Sixty-two eligible patients with symptoms of the common cold were randomized to either Immumax or placebo treatment groups for the duration of their symptoms or a maximum of 14 days. Resolution rates were estimated using Kaplan-Meier analysis, and resolution profiles were compared between groups using the log-rank test. The mean percentage change in total symptom severity scores at days 4 and 8 from baseline were compared between the two groups by one-way analysis of variance (ANOVA).

RESULTS

The median (interquartile range) time to resolution of all symptoms was 8 (5-9) days in the placebo group and 4 (3-6) days in the Immumax group. The results of the log-rank test indicate that symptoms resolved significantly faster in the Immumax group than in the placebo group (P < 0.001). The mean percentage reduction in total symptom severity scores from baseline at days 4 and 8 was significantly greater in the Immumax group than in the placebo group by one-way ANOVA (P < 0.01).

CONCLUSION

We can conclude from our study that Immumax is helpful in reducing the duration and severity of common cold symptoms.

摘要

目的

研究一种天然多草药配方(Immumax)对感冒患者的潜在疗效和耐受性,该配方含有 120 毫克西洋蒲公英提取物、100 毫克大蒜粉、200 毫克黑种草油和 50 毫克人参提取物以及 50 毫克维生素 C 和 7.5 毫克元素锌。

设计和设置

本研究采用前瞻性、双盲、随机、对照研究设计,在门诊环境中进行。

患者和方法

62 名符合感冒症状的合格患者随机分为 Immumax 或安慰剂治疗组,持续治疗至症状缓解或最长 14 天。采用 Kaplan-Meier 分析估计缓解率,并通过对数秩检验比较组间缓解情况。通过单向方差分析(ANOVA)比较两组患者在第 4 天和第 8 天总症状严重程度评分的平均百分比变化。

结果

安慰剂组所有症状缓解的中位数(四分位距)时间为 8(5-9)天,Immumax 组为 4(3-6)天。对数秩检验结果表明,Immumax 组症状缓解速度明显快于安慰剂组(P <0.001)。在第 4 天和第 8 天,与安慰剂组相比,Immumax 组总症状严重程度评分的平均百分比降低幅度通过单向 ANOVA 显著更大(P <0.01)。

结论

我们可以从我们的研究中得出结论,Immumax 有助于缩短普通感冒症状的持续时间和严重程度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/645b/3048339/9987d7e4b4f7/ijgm-4-045f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验